ISSN: 2155-6121
Journal of Allergy & Therapy
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Epinephrine Can Save Lives. Anaphylaxis, always a Challenge: A Therapeutic Approach on Children

Sur Genel1,2, Sur Maria1, Kudor-Szabadi Liana1, Sur Lucia1, Sur Daniel1 and Samasca Gabriel1,2*
1University of Medicine and Pharmacy, Iuliu Hatieganu, Cluj-Napoca, Romania
2Emergency Clinical Hospital for Children, Cluj-Napoca, Romania
Corresponding Author : Gabriel Samaşca
Department of Immunology, Croitorilor Street
19-21 No, Iuliu Haţieganu, University of Medicine and Pharmacy
Cluj- Napoca, Romania
E-mail: Gabriel.Samasca@umfcluj.ro
Received December 04, 2011; Accepted December 26, 2011; Published January 15, 2012
Citation: Genel S, Maria S, Liana KS, Lucia S, Daniel S, et al. (2012) Epinephrine Can Save Lives. Anaphylaxis, always a Challenge: A Therapeutic Approach on Children. J Aller Ther 3:e103. doi: 10.4172/2155-6121.1000e103
Copyright: © 2012 Genel S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Allergy & Therapy

Introduction
Anaphylaxis is a major emergency, it may have an unpredictable evolution, may progress rapidly to a fatal outcome if we don’t establish the correct diagnosis, that has to be followed by rapid treatment measures.
Anaphylaxis responds promptly to treatment with epinephrine, but new episodes may occur, or at least one new episode, so-called biphasic anaphylaxis, and clinicians always have to consider this situation. From an epidemiological point of view, in most countries there is no clear evidence of cases of anaphylaxis.
Correct management of anaphylaxis requires an accurate treatment of the first episode, identifying causes and preventing future episodes [1-9].
Epidemiology of Anaphylaxis
Anaphylaxis is defined as an acute disease (minutes or hours after exposure to the allergen) with skin manifestations (general hives, itch or flushing, swollen lips-tongue-uvula), respiratory manifestations (dyspnoea, wheezing, bronchospasm, stridor, reduced peak expiratory flow, hypoxemia), decreased blood pressure and other symptoms associated with organ dysfunction (collapse, syncope, hypotonia) [10-14]. These events occur after the contact with an allergen due to mast cell degranulation, after the circulation of preformed mediators (hystamine) and newly formed (leukotrienes) [15-18]. The incidence of anaphylaxis is estimated at 30 cases per 100.000 patients per year. Regarding mortality due to anaphylaxis, there is no rigorous evidence. If we consider the prescribed epinephrine, the incidence of the child would be 1-5 cases per 1000 patients [19-22].
It is believed that currently there is a growing tendency of anaphylaxis cases, due to widespread use of products with allergenic potential. During a year, at the Children’s Hospital from Cluj have been investigated for allergic manifestations 1180 children, of whom 533 were positive. The largest number were positive to mites (232 patients), other 140 patients to animal hair, 85 children to milk, 59 to pollen, 50 to milk proteins, 25 to eggs, 26 to molds and the rest to vegetables and fruits.
Anaphylaxis was observed in 3 children, of whom one died the patient arrived too late to the hospital and the treatment was no longer efficient. In the U.S. it is estimated that food is responsible for about 30.000 cases of anaphylaxis per year, with 2.000 hospitalizations and 200 deaths. For children, the risk of anaphylaxis is 1 in 2 years for foods with 0.6 to 5 % mortality per episode.
Clinical Diagnosis
Anaphylactic events are easily recognized by an experienced physician. Clinical manifestations occur in 1-15 minutes after exposure to allergen. In some cases, they can occur 30 minutes to an hour after exposure. The patient is unwell, becomes agitated, complains of tachycardia and tachypnea. Other symptoms like tingling sensations, itchy and flushed skin, throbbing in the ears, coughing, sneezing, hives and swelling (angioedema) may occur. Breathing may become difficult and wheezing may occur due to upper airways constriction and swelling. An anaphylactic reaction may progress so rapidly that it leads to collapse, cessation of breathing and loss of consciousness within 1-2 min. The reaction may be fatal unless treatment is applied immediately.
At presentation in the emergency room, anaphylaxis may not be recognised if it is triggered by a new agent, if it is an individual’s first episode, or if it’s an infant or a young child, or in an aphonic, dyspnoeic or unconscious individual.
The diagnosis of anaphylaxis is mainly based on the clinical history, and clinical criteria.
An anaphylactic episode is defined not only by the simultaneous involvement of two or more organs or systems, but mainly by the involvement of vital systems.
Anaphylaxis can present in various ways, in the major symptoms 60 % has to do with the skin (hive and flushing), but there can also be serious respiratory or cardiovascular failure, difficulty in breathing, swollen and tingling lips or a fall in a blood pressure leading to dizziness, nausea or pallor. As clinical manifestations can change, during a single episode at onset, a careful observation of the patient imposes.
The clinical presentation of anaphylaxis may vary: from one episode to another, with the time from to exposure to the trigger, the onset of symptoms, and the severity of symptoms [23-25].
Differential Diagnosis
When there is a history of recent exposure to a known allergen, anaphylaxis diagnosis is easy.
When cardiovascular and gastrointestinal manifestations predominate, diagnosis is more difficult.
Respiratory pathology
Respiratory distress syndrome; recent inhalation of foreign antibodies.
Neurological
Epileptic syndrome with hypotonia and loss of consciousness.
Flushing syndromes
Various agents have been involved in causing flushing: angiotensine converting enzyme inhibitors (histamine, kallicrein, nicotine) and carcinoid syndrome (flushing, diarrhea, colic and wheezing); medullar carcinoma of the thyroid is another important condition (persistent flushing of the face, hands and feet). Flushing syndrome is wet and dry. In the wet form caused by the postmenopausal state, sweating accompanies the flushing because of sympathetic cholinergic stimulation of the sweat gland. In carcinoid syndrome, dry flushing appears because sweat glands are not activated. In alcohol ingestion, flushing can also be present, especially within Asian people, who lack the aldehide dehydrogenase 2 enzyme. Alcohol can also lead to flushing in patients with Hodgkin’s disease, hypereosinophilia syndrome and splenectomy.
Restaurant syndrome
Scombroid-fish poisoning due to histamine has been described in adults and children (fish colonized by enterobacteria - Klebsiella oxytoca and Morganella morgani) can contain histamine derivated from histidine through bacterial action. The Chinese restaurant syndrome caused by monosodium glutamate in foods may also provoke flushing, headache and abdominal symptoms.
Sulphites from preservatives in gelatin, sauces, wine, fruit juices, cheese, mollusks can cause the same symptoms as monosodium glutamate.
Vasovagal reactions are a reflex of the involuntary nervous system causing bradycardia, hypotension and vasodilatation. Vasovagal syndromes are generally caused by physical or emotional stress and characterized by pallor, asthenia,nausea,hypotension,vomiting and profuse sweating.
Excess of endogenous histamine production
The Vancomycin induced red man syndrome, mediated by histamine systemic mastocytosis can determinate anaphylactic acute syndrome.
Promyelocytic leukemia and basophilic leukemia treated with Treonin can also cause anaphylactic reaction.
Echinococal cysts may be a possible cause of anaphylactic episode via histamine.
Psychogenic conditions
Munchausen syndrome, globus hystericus and panic attacks cam imitate anaphylactic symptoms.
 
Another allergic manifestation
Hereditary angioedema can mimic anaphylactis attacks. These patients have usually had episodes triggered by trivial traumas such as oral or dental manipulations. Prompt recongnition of this attacks may be critical, as long as oedema of the tongue and upper airways is the cause of death in 15-30 % of this patients.
The systemic capillary leak symdrome, a severe sometimes fatal idiophatic condition with shock and massive edema, often after a nonspecific prodrome of weakness, fatigue, and myalgias is also one of the differential diagnosis.
Gleich’s syndrome is characterized by episodic urticaria/ angioedema, hypereosinophilia and elevation of immunoglobulin M [26-32].
Laboratory Diagnosis
The diagnosis is primarly clinical but laboratory tests may bring additional information: IgE mediated anaphylaxis. More valuable is the measurement of metabolites such as: tryptase, plasma and urinary Histamine [33-36].
Emergency Treatment of Anaphilaxis
The elements of the intervention to be rapidly activated can be summarized in the mneomonic airway patency, breathing, circulation and mental status (ABCM). The patient must be kept horizontal, with raised legs, to promote the perfusion of vital organs [37-39].
Epinephrine must be injected intramuscular (s.c is not recommended because local vasoconstriction can reduce deposition. The substance should be injected intramusculary in the tigh, on the lateral part of the quadriceps or in the deltoid muscle.
The dose is 0.01mg/kg of aqueous Epinephrine 1:100 (up to 0.5 ml to be repeated if necessary after 5-30 minutes).
If the patient’s weight is unknown, an approximate dosage is 50 μg (50 μg-0.05 ml for infants less then 6 months; 120 μg-0.12 ml for children between 6 month to 6 years; 250 μg-0.25 ml from 6 to 12 years; 500 μg-0.5 ml for children older than 12 years).
During the administration of Epinephrine, vital signs-cardiac activity, respiratory function and blood pressure should be continuously monitored and airways patency should be continuously maintained to prevent rapid worsening.
If symptoms do not decrease:
1. Repeat Epinephrine after 5 minutes;
2. Establish a venuous acces; in hypotension rapidly administer isotonic saline solution, 20-30 ml/h in the first hour;
3. If hypotension persists rapid diffusion of volume expanders;
4. Administer oxygen: 5-8 l/min;
5. Administer support drugs: antihistamines (Clorpheniramine), bronchodilators (Salbutamol), corticosteroids (Hydrocortisone), glucagons, Dopamine.
Antihistamines are indicated for treatment of pruritus and urticaria. Clorpheniramine is used in a dose of 1 mg/kilo; other antihistamines: Levocetirizine, Desloratadine.
Salbutamol can be used for relief of bronchospasm.
Methylprednisolone is used in a dose of 1-2 mg/day i.v.
Biphasic Anaphylaxis can be developed after as many 20 % of anaphylaxis. The interval between the first anaphylactic reaction and the subsequent fatal or near fatal anaphylactic episode can last between 2 to 12 hours, and no specific symptom is predictive of recurrences. One Ephinephrine injection is similar to first episode ?? Systemic corticosteroids are unable to prevent recurrence [40-44].
Conclusion
The emergency department is very important for anaphylaxis treatment and the prevention of subsequent recurrences.
References
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11172
  • [From(publication date):
    March-2012 - Aug 26, 2016]
  • Breakdown by view type
  • HTML page views : 7440
  • PDF downloads :3732
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version